1、炎症、代谢与肝脏肿瘤；2、腔镜肝切除技术与临床应用
详细工作介绍
1、代谢酶与肝癌进展的相关临床与机理研究：我们研究发现肝癌癌变过程中，谷氨酰胺酶有GLS2转化为GLS1，且GLS1与肝癌转移、预后密切相关（Oncotarget, 2015）；当前我们正在进行多中心临床，同时申请了国家专利诊断试剂盒，并成功构建表达GLS1和2的载体。另外，我们针对靶向抑制PDK的DCA，深入研究DPDA诱导肿瘤自噬，协同化疗、放疗等治疗肿瘤，我们旨在进一步研究肿瘤代谢与转移、肝癌代谢相关独特性、验证代谢相关诊断标记物、研发针对代谢的药物，并临床转化。
1) Dong G, Mao Q, Yu D, Zhang Y, Qiu M, Dong G, Chen Q, Xia W, Wang J, Xu L, Jiang F. Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy. Sci Rep. 2017 Feb 7;7:42060. doi: 10.1038/srep42060. PubMed PMID: 28169357; PubMed Central PMCID: PMC5294420. (co-first author)
2) Su L, Zhang H, Yan C, Chen A, Meng G, Wei J, Yu D, Ding Y. Superior anti-tumor efficacy of diisopropylaminedichloroacetate compared with dichloroacetate in a subcutaneous transplantation breast tumor model. Oncotarget. 2016 Oct 4;7(40):65721-65731. doi: 10.18632/oncotarget.11609. PubMed PMID: 27582548; PubMed Central PMCID: PMC5323187.( corresponding author, 5.008, III区)
3) Yu D, Shi X, Meng G, Chen J, Yan C, Jiang Y, Wei J, Ding Y. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget. 2015 Apr 10;6(10):7619-31. PubMed PMID: 25844758; PubMed Central PMCID: PMC4480704. 6.359
4) Yu DC, Liu J, Chen J, Shao JJ, Shen X, Xia HG, Li CJ, Xue B, Ding YT. GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis. BMC Cancer. 2014 Apr 9;14(1):248. doi: 10.1186/1471-2407-14-248. PubMed PMID: 24716791; PubMed Central PMCID: PMC4028285 3.362
2、血管新生与肝脏肿瘤：内皮祖细胞（EPCs）归巢肝癌组织和癌旁组织，参与肝癌血管新生，与肝癌早期复发成显著正相关；EPCs调控肿瘤生物学行为，促进肿瘤转移；肝癌癌旁独特的血管新生为肝癌肝内转移提供独特的微环境。研究结果发表于Clinical Cancer Research、BMC Cancer和Endothelium等。血管新生的后续研究成功申请了多项自然基金。在肿瘤靶向治疗方面，与南京航空航天大学陈达院士课题组合作，研究纳米碳管靶向治疗肝癌，研究结果先后发表于纳米相关的权威杂志Small, Carbon和Nanotechnology。2015年，课题“肝细胞癌血管新生微环境和靶向治疗研究”获江苏省医学奖二等和中华医学奖三等奖。
1) Decai Yu, Wendu Feng, Xianbiao Shi, Zhiyong Wang, Wei Ge, Chunping Jiang, XitaiSun, Yitao Ding. Dynamic analysis for gene expression profiles of endothelial colony forming cells under hypoxia. Genes Genom (2013) 35:451–462. 0.596
2) Decai Yu, Qingguo Li, Xiwei Ding and Yitao Ding. Circulating MicroRNAs: Potential Biomarkers for Cancer. Int. J. Mol. Sci. 2011, 12(3), 2055-2063. 2.862
3) Decai Yu, Jun chen,Xitai Sun, Linyuan Zhuang, Chunping Jiang, Yitao Ding. Mechanism of endothelial progenitor cell recruitment into neo-vessels in adjacent non-tumor tissues in hepatocellular carcinoma. BMC Cancer. 2010 Aug 17;10:435.
4) Decai Yu, Jun chen,andYitao Ding. Hypoxic and Highly Angiogenic Non-Tumor Tissues Surrounding Hepatocellular Carcinoma: The ‘Niche’ of Endothelial Progenitor Cells. Int. J. Mol. Sci. 2010, 11(8), 2901-2909 2.862
5) Bin Kang, Decai Yu, Yaodong Dai, Shuquan Chang, Da Chen, YitaoDing.Cancer-cell targeting and photoacoustic therapy using carbon nanotubes as "bomb" agents. Small.2009 Jun;5(11):1292-301. (co-first author) 8.368
6) Bin Kang, Decai Yu, Yaodong Dai, Shuquan Chang, Da Chen, YitaoDing.Biodistribution and accumulation of intravenously administered carbon nanotubes in mice probed by Raman spectroscopy and fluorescent labeling. Carbon 2009,47(4):1189-1192(co-first author) 6.196
7) Bin Kang, Decai Yu, Shuquan Chang, Da Chen, Yaodong Dai, Yitao Ding. Intracellular uptake, trafficking and subcellular distribution of folate conjugated single walled carbon nanotubes within living cells. Nanotechnology 2008;19 375103. (co-first author) 6.196
8) Decai Yu, Xitai Sun, YudongQiu, Jianxing Zhou, Yafu Wu, Lingyuan Zhuang, Jun Chen, Yitao Ding. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res. 2007, 13(13): 3814-24. (highlighted points.) 8.722
9) Decai Yu, Xitai Sun, Shen Fang, Ziqiang Chao, KuiMeng, Yitao Ding. Validation of endothelial progenitor cells in human umbilical veins and the isolated endothelial cells. Endothelium. 2007, 14(3): 141-50.
10) Decai Yu, Linyuan Zhuang, Xitai Sun, Jun Chen, Yongzhong Yao, KuiMeng, Yitao Ding. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer. 2007, 7:122.
11) Decai Yu, Jun Chen, Xitai Sun, Yitao Ding. Mechanism on the recruitment of EPCs into neovessels in adjacent non-tumor tissues with hepatocellular carcinoma. Hepatology Int 2008, 2: S64.
3、肝癌生物治疗：搭建抗肿瘤代谢、诱导肿瘤免疫相关的溶瘤病毒，联合其他肿瘤治疗手段，改善预后。
1) Meng G, Xia M, Wang D, Chen A, Wang Y, Wang H, Yu D, Wei J. Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells. Oncotarget. 2014 Aug 15;5(15):6365-74.（corresponding author） 6.359
4、腔镜肝切除技术与临床应用研究：在肝脏外科技术研究方面，临床主要围绕肝癌开展以手术为主的综合治疗，包括腹腔镜肝切除、肝移植、射频及药物等；前期自行研发肝脏直线切割器和肝门阻断带，并将进一步市场转化。逐步建立肝癌组织库，为肝癌生物标志物的筛选及治疗等方面的奠定基础。
1) De-Cai Yu, Xing-Yu Wu, Xi-Tai Sun, Yi-Tao Ding. Glissonian approach combined with major hepatic vein first for laparoscopic anatomic hepatectomy. Hepatobiliary & Pancreatic Diseases International.Available online 25 June 2018
2) Wei Ge, Yi Wang, Ya-Juan Cao, Min Xie, Yi-Tao Ding, Ming Zhang, De-Cai Yu. Radiological score for hemorrhage in the patients with portal hypertension. Int J ClinExpPathol 2015;8(9): 11517-23 （corresponding author） 1.891
3) Decai Yu, Weibo Chen, Chunping Jiang, Yitao Ding. Risk assessment in patients undergoing liver resection. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):473-9. 1.517
4) 余德才,吴星宇. 以尾状叶为中心解剖性肝切除的临床定义与意义[J]. 中华腔镜外科杂志(电子版),2017,10(03):131-135.
5) 王超,余德才,吴星宇,孙喜太. 腹腔镜下Glisson蒂横断法肝段切除策略[J]. 中华普外科手术学杂志(电子版),2017,11(05):380-382.
6) 王超,余德才. 腹腔镜下Glisson蒂横断法肝段切除[J]. 中华普外科手术学杂志(电子版),2017,11(05):374.
7) 余德才,吴星宇,颜晨,丁义涛. 腹腔镜下Glisson鞘肝蒂解剖法右半肝切除:两例报道(附视频)[J]. 中华肝脏外科手术学电子杂志,2017,6(05):422-424.
